Weiss Ratings Reiterates Sell (E+) Rating for Agape ATP (NASDAQ:ATPC)

Key Points

• Weiss Ratings has reaffirmed a "sell (E+)" rating for Agape ATP (NASDAQ:ATPC) in a recent research report, signaling continued skepticism about the company's stock performance.
• Agape ATP's stock saw a slight increase of 0.4%, trading at $1.17, despite having a negative net margin of 183.13% and a negative return on equity of 20.32% reported in its latest quarterly earnings.
• The company's market capitalization stands at $58.51 million, with a price-to-earnings ratio of -2.85, highlighting concerns over its financial health.

Agape ATP (NASDAQ:ATPC - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Agape ATP Trading Up 0.4%

Agape ATP stock traded up $0.01 during midday trading on Wednesday, hitting $1.17. 10,453 shares of the stock were exchanged, compared to its average volume of 1,180,737. Agape ATP has a fifty-two week low of $0.90 and a fifty-two week high of $2.93. The stock has a market capitalization of $58.51 million, a price-to-earnings ratio of -2.85 and a beta of -0.95. The stock's 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.50.

Agape ATP (NASDAQ:ATPC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.01) earnings per share for the quarter. Agape ATP had a negative net margin of 183.13% and a negative return on equity of 20.32%.

Agape ATP Company Profile

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.